Previous 10 | Next 10 |
Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada PR Newswire SAN DIEGO , Sept. 19, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicat...
2023-08-29 09:15:36 ET Clinical-stage biopharmaceutical company Inhibrx ( NASDAQ: INBX ) entered into a securities purchase agreement for a private placement financing that is expected to result in gross proceeds of ~$200M. In the PIPE, Inhibrx ( INBX ) is selling an agg...
Inhibrx Announces $200 Million Private Placement Financing PR Newswire SAN DIEGO , Aug. 29, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for...
2023-08-17 16:41:26 ET Summary INBX is researching a breakthrough for Alpha-1 Antitrypsin deficiency and has received regulatory support for its INBRX-101 pipeline. The AATD treatment market is expected to experience robust growth in the coming years. INBRX-101 has received Fa...
Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights PR Newswire SAN DIEGO , Aug. 7, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), or Inhibrx, or the Company, a biopharmaceutical company with four programs in ongoing clinical...
2023-05-30 09:33:22 ET Inhibrx, Inc. ( NASDAQ: INBX ) announced Tuesday that the FDA granted Fast Track designation for its experimental therapy INBRX-101 as a treatment for patients with emphysema due to alpha-1 antitrypsin deficiency (AATD). Characterized by damaged air sacs...
Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency PR Newswire SAN DIEGO , May 30, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of ...
2023-05-08 17:03:19 ET Inhibrx press release ( NASDAQ: INBX ): Q1 GAAP EPS of -$1.12. Cash and Cash Equivalents. As of March 31, 2023, Inhibrx had cash and cash equivalents of $234.3 million, compared to $273.9 million as of December 31, 2022. For further d...
Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights PR Newswire SAN DIEGO , May 8, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), or Inhibrx, or the Company, a biopharmaceutical company with four clinical programs in developme...
2023-05-04 16:20:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended March 31, 2023, Baron Health Care Fund declined 3.69%, compared w...
News, Short Squeeze, Breakout and More Instantly...
Inhibrx Inc. Company Name:
INBX Stock Symbol:
NASDAQ Market:
2024-05-31 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Fuse Medical Inc (FZMD) is expected to report for Q1 2024 PhoneX Holdings Inc (PXHI) is expected to report for Q1 2024 Avalon GloboCare Corp. (ALBT) is expected to report for Q1 2024 Ricoh Company Ltd ADR (RICOY) is expected to report for Q4 2024 Amplitech Group Inc. (AMPG) is exp...
Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi PR Newswire SAN DIEGO , May 24, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") announced that, at a special meeting (the "Special Meeting"), the Company'...